REDWOOD CITY, CA, USA I January 5, 2015 I OncoMed Pharmaceuticals, Inc. (OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced dosing of the first patient in its anti-DLL4/VEGF bispecific antibody (OMP-305B83) Phase 1a clinical trial. The anti-DLL4/VEGF bispecific antibody is designed to have both anti-cancer stem cell and anti-angiogenic activity.
“This is the sixth novel product candidate discovered by OncoMed researchers and the second product from our multi-billion dollar collaboration with Celgene to be advanced to the clinic by our development team,” said Paul J. Hastings, OncoMed’s Chairman and Chief Executive Officer. “This antibody leverages the clinical experience gained with our anti-DLL4 antibody, demcizumab, which has demonstrated encouraging early signs of clinical activity in Phase 1b clinical trials.”
Jakob Dupont, M.D., OncoMed’s Chief Medical Officer, added, “The combined inhibition of DLL4 and VEGF with this bispecific has demonstrated robust preclinical activity against a number of solid tumor types. In this trial, we look forward to establishing a suitable dose and exploring this antibody’s safety and initial efficacy. We also plan to advance this bispecific antibody to Phase 1b trials, in combination with standard of care in select solid tumors.”
The single-agent Phase 1a trial is enrolling patients with advanced refractory solid tumors. The open-label dose-escalation study is designed to assess the safety, pharmacokinetics, pharmacodynamics and initial evidence of efficacy of the anti-DLL4/VEGF bispecific antibody. The trial is being conducted at four sites in the United States.
The bispecific antibody was discovered using OncoMed’s proprietary MAbTrap(TM) antibody display technology, which enables the rapid identification of monoclonal antibodies that bind targets with high affinity and specificity. The antibody is the first program based on OncoMed’s BiMAb(TM) bispecific platform technology, which enables bispecific antibodies with traditional antibody shape, to enter clinical testing. In preclinical studies OncoMed’s anti-DLL4/VEGF bispecific antibody demonstrated robust in vivo anti-tumor efficacy across a range of solid tumor xenografts, including colon, lung and pancreatic cancers, among others. The bispecific antibody delayed tumor recurrence following termination of chemotherapy, and decreased the frequency of cancer stem cells. Further, dual inhibition of DLL4 and VEGF appears to exhibit synergistic anti-tumor activity at doses where blockade of either target alone elicited sub-optimal activity.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has six anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-Notch1 (OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28), which each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed plans to file an Investigational New Drug application in early 2015 for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signalling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company’s website: www.oncomed.com.
SOURCE: OncoMed Pharmaceuticals
Post Views: 31
REDWOOD CITY, CA, USA I January 5, 2015 I OncoMed Pharmaceuticals, Inc. (OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced dosing of the first patient in its anti-DLL4/VEGF bispecific antibody (OMP-305B83) Phase 1a clinical trial. The anti-DLL4/VEGF bispecific antibody is designed to have both anti-cancer stem cell and anti-angiogenic activity.
“This is the sixth novel product candidate discovered by OncoMed researchers and the second product from our multi-billion dollar collaboration with Celgene to be advanced to the clinic by our development team,” said Paul J. Hastings, OncoMed’s Chairman and Chief Executive Officer. “This antibody leverages the clinical experience gained with our anti-DLL4 antibody, demcizumab, which has demonstrated encouraging early signs of clinical activity in Phase 1b clinical trials.”
Jakob Dupont, M.D., OncoMed’s Chief Medical Officer, added, “The combined inhibition of DLL4 and VEGF with this bispecific has demonstrated robust preclinical activity against a number of solid tumor types. In this trial, we look forward to establishing a suitable dose and exploring this antibody’s safety and initial efficacy. We also plan to advance this bispecific antibody to Phase 1b trials, in combination with standard of care in select solid tumors.”
The single-agent Phase 1a trial is enrolling patients with advanced refractory solid tumors. The open-label dose-escalation study is designed to assess the safety, pharmacokinetics, pharmacodynamics and initial evidence of efficacy of the anti-DLL4/VEGF bispecific antibody. The trial is being conducted at four sites in the United States.
The bispecific antibody was discovered using OncoMed’s proprietary MAbTrap(TM) antibody display technology, which enables the rapid identification of monoclonal antibodies that bind targets with high affinity and specificity. The antibody is the first program based on OncoMed’s BiMAb(TM) bispecific platform technology, which enables bispecific antibodies with traditional antibody shape, to enter clinical testing. In preclinical studies OncoMed’s anti-DLL4/VEGF bispecific antibody demonstrated robust in vivo anti-tumor efficacy across a range of solid tumor xenografts, including colon, lung and pancreatic cancers, among others. The bispecific antibody delayed tumor recurrence following termination of chemotherapy, and decreased the frequency of cancer stem cells. Further, dual inhibition of DLL4 and VEGF appears to exhibit synergistic anti-tumor activity at doses where blockade of either target alone elicited sub-optimal activity.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has six anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-Notch1 (OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28), which each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed plans to file an Investigational New Drug application in early 2015 for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signalling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company’s website: www.oncomed.com.
SOURCE: OncoMed Pharmaceuticals
Post Views: 31
